Wednesday, October 07 2026

Pharma listed cos: FY26 profits surge 28pc to Rs42.2bn YoY
Profitability of Pakistan’s listed pharmaceutical sector increased 28 percent year-on-year (YoY) to Rs42.2 billion in FY26, mainly supported by price-led growth and lower finance costs, according to a Research report issued. However, sector earnings declined 2 percent YoY and 26 percent quarter-on-quarter (QoQ) in 4QFY26, primarily due to the loss posted by The Searle Company Limited (SEARL) during the quarter. Excluding SEARL, sector profitability increased 6 percent YoY but declined 4 percent QoQ to Rs9.3 billion in 4QFY26.
Related news categories: business economic-indicators pharma psx stock-exchanges

Wednesday, September 23 2026

MACTER FY26 profit softens 14%
Macter International Limited (PSX: MACTER) reported a 14% drop in its consolidated net profit for the fiscal year ended June 30, 2026, recording Rs675.17m compared to Rs786.93m in the preceding year. Reflecting this bottom-line compression, basic and diluted earnings per share (EPS) for the year stood at Rs14.83, down from Rs16.95 in FY25. The primary factor weighing on final earnings was higher taxation outlays and selling expense inflation, which offset a strong 17% expansion in top-line revenue. Consolidated revenue from contracts with customers grew by 17% year-on-year to Rs12.17bn, up from Rs10.36bn in FY25. Cost of sales expanded by 11% to Rs6.25bn, allowing gross profit to increase 25% to Rs5.92bn compared to Rs4.73bn in the prior year.
Related news categories: business economic-indicators misc pharma